Health‐related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient‐reported outcomes from the APOLLO trial

Terpos, Evangelos; Dimopoulos, Meletios Α.; Boccadoro, Mario; Delimpasi, Sosana; Beksaç, Meral; Katodritou, Eirini; Moreau, Philippe; Pompa, Alessandra; Symeonidis, Argiris; Bila, Jelena; Oriol, Albert; Mateos, María‐Victoria; Einsele, Hermann; Orfanidis, Ioannis; Gries, Katharine S.; Fastenau, John; Liu, Kevin; He, Jianming; Kampfenkel, Tobias; Qiu, Yanping; Amin, Himal; Carson, Robin; Sonneveld, Pieter

doi:10.1002/ajh.26480

Cited by 8 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Final OS analysis for this study is still pending but given the safety profile of Isa-Pd in the clinical trial we expect continued survival benefits as data mature. While overall survival data has yet to mature for patients receiving Dara-Pd in APOLLO, a recent publication of patient-reported outcomes (PROs) showed substantial improvement in pain, functional status, and disease-related symptoms compared to POM-dex [92]. How these findings of efficacy and safety persist over a longer duration of follow-up and in the real-world setting continues to be assessed.…”

Section: Use Of Monoclonal Antibody Therapymentioning

confidence: 99%

Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse

2023

View full text Add to dashboard Cite

Multiple myeloma remains an incurable disease with the usual disease course requiring induction therapy, autologous stem cell transplantation for eligible patients, and long-term maintenance. Risk stratification tools and cytogenetic alterations help inform individualized therapeutic choices for patients in hopes of achieving long-term remissions with preserved quality of life. Unfortunately, relapses occur at different stages of the course of the disease owing to the biological heterogeneity of the disease. Addressing relapse can be complex and challenging as there are both therapy- and patient-related factors to consider. In this broad scoping review of available therapies in relapsed/refractory multiple myeloma (RRMM), we cover the pharmacologic mechanisms underlying active therapies such as immunomodulatory agents (IMiDs), proteasome inhibitors (PIs), monoclonal antibodies (mAbs), traditional chemotherapy, and Venetoclax. We then review the clinical data supporting the use of these therapies, organized based on drug resistance/refractoriness, and the role of autologous stem cell transplant (ASCT). Approaches to special situations during relapse such as renal impairment and extramedullary disease are also covered. Lastly, we look towards the future by briefly reviewing the clinical data supporting the use of chimeric antigen receptor (CAR-T) therapy, bispecific T cell engagers (BITE), and Cereblon E3 Ligase Modulators (CELMoDs).

show abstract

Section: Use Of Monoclonal Antibody Therapymentioning

confidence: 99%

Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse

2023

View full text Add to dashboard Cite

show abstract

“…Additionally, the APOLLO trial suggested that patients aged ≥65 years had the highest likelihood of exhibiting significant favorable differences in the least squares mean change from the baseline in GHS, pain, physical functioning, and emotional functioning, favoring D-Pd [ 102 ]. In any case, the benefits of DARA-containing regimens in the context of RRMM patients are supported from the perspective of their impact on QOL.…”

Section: The Effect Of Dara-containing Regimens On the Qol In Elderly...mentioning

confidence: 99%

Daratumumab Treatment for “Truly Frail” Elderly Myeloma Patients

Horigome,

Suzuki,

Suzuki

2024

Life

View full text Add to dashboard Cite

Remarkable advancements have been made in the treatment outcomes of multiple myeloma (MM) patients; however, for frail elderly patients, these treatment outcomes are still insufficient. Elderly MM patients are increasing, as are their treatment regimens. There is a heightened demand to assess these patients in order to provide optimized treatments. While continuous treatment is more common for MM patients when compared to fixed-duration treatment, due to the risk of treatment interruption causing reduced survival rates, effectiveness and safety are essential. Treatment goals vary for each patient, but must preserve their quality of life (QOL). When planning treatments for these patients, frailty evaluation is increasingly emphasized as a stratification factor which helps develop accurate screening tools. Daratumumab (DARA) therapy, used globally, is not only effective in frail elderly MM patients, but also has QOL benefits. Proficiency in utilizing DARA regimens is potentially advantageous for patients not included in clinical trials, and innovative usage can further broaden its scope. The development of tools to accurately assess frailty and the establishment of optimal treatments for frail elderly MM patients are imperative. This review is an overview, challenging the frailty assessments for MM patients, re-examining the evidence for DARA regimens in frail elderly MM patients, and discussing potential areas for improvement.

show abstract

“…In the phase III APOLLO study of pomalidomide plus dexamethasone with or without daratumumab, HRQoL measured using the EORTC QLQ-C30 and EORTC QLQ-MY20 questionnaires remained generally consistent with baseline in both arms, although between-group differences did not favor the pomalidomide-dexamethasone arm for most QoL scales. 14 In the phase II DREAMM-2 study, HRQoL measured by the EORTC QLQ-MY20 scale was maintained with long-term follow-up with belantamab mafodotin, with only up to 38% of evaluable patients (n=45) experiencing improvements in pain in different locations at week 7. 15 …”

mentioning

confidence: 99%

Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study

Schjesvold,

Ludwig,

Delimpasi

et al. 2024

haematol

View full text Add to dashboard Cite

show abstract

Health‐related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient‐reported outcomes from the APOLLO trial

Cited by 8 publications

References 40 publications

Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse

Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse

Daratumumab Treatment for “Truly Frail” Elderly Myeloma Patients

Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study

Contact Info

Product

Resources

About